For the patients, the appearance of the inhaled drug therapy has been a significant advantage with the respiratory disorders such as COPD and the asthma due to its painless and flexible administration when equated to the injections. There are several types of the inhalation systems obtainable in the market, and these involve inhalers and nebulizers. The two greatest frequent prevalent respiratory disorders are the asthma and COPD.
According to the report analysis, ‘US Inhalation Systems Market Forecast up to 2024’ states that there are several key players which are presently functioning in this sector more actively for dominating the highest value of market share and leading the fastest market growth in the short span of time while increasing the prevalence of the respiratory diseases, effective advancements in the technology and decreased in the side effects allied with the drug inhalation includes Omron Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Inspiro Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan Medical Corporation, GlaxoSmithKline plc, Becton Dickinson.
According to the WHO, approximately 235 million people are presently suffering from the asthma, and it is very much general in the children. The Chronic respiratory disease such as asthma and COPD are accountable for the considerable financial and health burden in the US, and in 2015, 6.7% death in the US were owing to the chronic respiratory disorders. Moreover, chronic obstructive pulmonary disease is the third important reason of death around the globe, in 2016 accounting for approximately 3 million deaths. State of West Virginia has the uppermost pervasiveness of COPD, and nearby 12% of the populace are detected with COPD.
However, in the present years, there is an augment in the approvals owing to the acceptance of the systems and also the drug companies are introducing the new inhalation systems and cooperating with the other vendors to enhance the innovative devices in the market. For instance, in February 2017, FDA permitted two products advanced by Teva Pharmaceutical Industries Ltd., ArmonAir RespiClick and AirDuo RespiClick, to delight the adolescent and adult patients with asthma.
Additionally, the US Inhalation Systems Market is predicted to witness an effective CAGR of 5.8% during the forecast period of 2018-2024. Whereas, the market of inhalation systems in US is segmented into different sectors which majorly involves products, applications and end-users. Whereas, based on the end user, the market is further divided into hospitals, ambulatory care centers, and home care centers. For instance, the hospitals attained a major market share in 2017, and home care sector is predicted to increase during the forecast period owing to the ease in the utilization of modern products, less homecare cost, and the accessibility of reimbursement.
Although, the US inhalation systems market is fueled by an upsurge in the prevalence of respiratory diseases, augmenting the geriatric population, and favorable reimbursement. Therefore, in the coming years, it is predicted that the market of inhalation systems in US will increase more positively over the recent few years.
To know more, click on the link below:-
US Inhalation Systems Market
Ankur Gupta, Head Marketing & Communications